ストックスクリーナーアプリを入手
31.84
0.06%
0.02
アフターアワーズ：
31.84
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor EventSlideshow (NASDAQ:AGIO) 2026-06-15 - Seeking Alpha
Agios to discontinue candidate for myelodysplastic syndromes - MSN
Agios Pharmaceuticals (AGIO) Reports Promising Results from Phas - GuruFocus
Agios Pharmaceuticals touts mitapivat gains despite sickle cell pain miss - MSN
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss - Yahoo Finance
AGIO: Mitapivat shows durable efficacy in rare hematology, supporting growth and pipeline expansion - TradingView
Technical Reactions to AGIO Trends in Macro Strategies - Stock Traders Daily
Agios presents detailed mitapivat trial results for sickle cell - Investing.com UK
Agios presents detailed mitapivat trial results for sickle cell By Investing.com - Investing.com Australia
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease - The Manila Times
Agios Pharmaceuticals Reports Positive Phase 3 Results for Mitapivat in Sickle Cell Disease, Highlighting Hemoglobin Response and Reduced Transfusion Burden - Quiver Quantitative
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong ... - Caledonian Record
Sickle cell patients needed fewer transfusions with Agios pill in Phase 3 - Stock Titan
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $31 - Moomoo
GW&K Investment Management LLC Purchases 354,359 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Announces Target Price $31 - Moomoo
Capital International Investors Buys New Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Shares Bought by BNP Paribas Financial Markets - MarketBeat
‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios - BioWorld News
Eyes on Asia: Olix, Agios, Eli Lilly - BioXconomy
Analysts’ Top Healthcare Picks: McKesson (MCK), Agios Pharma (AGIO) - The Globe and Mail
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Alpha Thalassemia Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Forma Therapeutics, Genmedicn Biopharma, Bristol-Myers Squibb, Agios Pharma - Barchart.com
Erste Asset Management GmbH Acquires 40,000 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
The week in pharma: action, reaction and insight – week to June 5, 2026 - The Pharma Letter
Why Agios Pharmaceuticals (AGIO) Is Down 5.4% After Overhauling Its Hematology PortfolioAnd What's Next - Sahm
Agios Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Q2 EPS Estimate for Agios Pharmaceuticals Reduced by Analyst - MarketBeat
AGIO secures global rights to late-stage rare blood disorder candidate - MSN
How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO) - Yahoo Finance
HC Wainwright Issues Optimistic Estimate for AGIO Earnings - MarketBeat
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate - The Globe and Mail
Trading the Move, Not the Narrative: (AGIO) Edition - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Agios Pharma (AGIO), Cogent Biosciences (COGT) - The Globe and Mail
Agios inks global licensing agreement with Oscotec - The Pharma Letter
Oscotec Signs Up to $665 Million Licensing Deal with Agios Pharmaceuticals for Autoimmune Drug Candidate Cevidoplenib - 알파경제
Agios Halts Tebapivat Trials As Sickle Cell Focus Shapes Valuation - Sahm
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare HematologySlideshow (NASDAQ:AGIO) 2026-06-01 - Seeking Alpha
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib - Yahoo Finance
Agios scraps blood cancer drug program after study miss - AOL.com
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - The Globe and Mail
AGIO: Cevidoplenib licensed for ITP, with strong phase II data and phase III planned for 2028 - TradingView
Agios licenses oral SYK inhibitor for rare blood disorder By Investing.com - Investing.com South Africa
Agios Pharmaceuticals (AGIO) Forms Licensing Deal for Cevidoplen - GuruFocus
AGIO: Exclusive global license for cevidoplenib expands rare hematology pipeline and targets ITP - TradingView
Agios licenses oral SYK inhibitor for rare blood disorder - Investing.com UK
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib - The Manila Times
Agios Pharmaceuticals Secures Exclusive Global Rights to Next-Generation SYK Inhibitor Cevidoplenib for Immune Thrombocytopenia Treatment - Quiver Quantitative
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize ... - Caledonian Record
Rare blood disorder drug deal gives Agios shot at $1B U.S. sales - Stock Titan
Oscotec licenses autoimmune drug to US Agios in deal up to 1 trillion wonCHOSUNBIZ - Chosunbiz
Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO) - MSN
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):